…
Drugs Made In America Acquisition II Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combination with one or more businesses. The company was incorporated in 2024 and is based in Fort Lauderdale, Florida.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Drugs Made In America Acquisition II Corp. is a special-purpose acquisition company formed to identify and combine with a business and appears focused on U.S.-based pharmaceutical manufacturing and supply-chain onshoring. Long-term growth drivers may include rising demand for domestic drug production, potential government support for supply-chain resilience, and consolidation opportunities in contract manufacturing, which could make the SPAC a way to gain thematic exposure without selecting an operating company.
Principal risks include absence of operating history prior to a business combination, reliance on completing a value-accretive merger within the SPAC's timeframe, sponsor conflicts and shareholder dilution, and sector-specific regulatory, capital-intensity and execution risks for any acquired target.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Type | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 |
| Income before tax | 4.19M | -0.15M |
| Net income | 4.19M | -0.15M |
| Selling general administrative | 0.49M | - |
| Ebitda | -1.30M | -0.15M |
| Operating income | -1.30M | -0.15M |
| Other operating expenses | 1.30M | 0.15M |
| Interest income | 4.93M | - |
| Net interest income | 4.93M | - |
| Total revenue | 0.00M | - |
| Total operating expenses | 1.30M | 0.15M |
| Total other income expense net | 5.49M | - |
| Net income from continuing ops | 4.19M | - |
| Breakdown | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Type | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 |
| Total assets | 504.96M | 0.14M |
| Other current assets | 0.03M | 0.04M |
| Total liab | 17.80M | 0.25M |
| Total stockholder equity | 487.16M | -0.12M |
| Other current liab | 0.20M | 0.00M |
| Common stock | 504.94M | 0.00M |
| Capital stock | 504.94M | 0.00M |
| Retained earnings | -17.78M | -0.15M |
| Cash | 0.00M | 0.02M |
| Total current liabilities | 0.30M | 0.25M |
| Net debt | -0.00M | 0.23M |
| Short term debt | - | 0.25M |
| Short long term debt | - | 0.25M |
| Short long term debt total | - | 0.25M |
| Other stockholder equity | - | 0.03M |
| Total current assets | 0.03M | 0.06M |
| Accounts payable | 0.10M | 0.00M |
| Non currrent assets other | 504.93M | 0.08M |
| Non current assets total | 504.93M | 0.08M |
| Breakdown | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Type | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 |
| Investments | -500.00M | - |
| Total cashflows from investing activities | -500.00M | - |
| Net borrowings | -0.53M | - |
| Total cash from financing activities | 501.00M | 0.21M |
| Net income | 4.19M | -0.15M |
| Change in cash | -0.02M | 0.02M |
| Begin period cash flow | 0.02M | - |
| End period cash flow | 0.00M | 0.02M |
| Total cash from operating activities | -1.02M | -0.19M |
| Issuance of capital stock | 502.00M | - |
| Other cashflows from investing activities | -500.00M | - |
| Change to account receivables | -0.81M | - |
| Other cashflows from financing activities | 501.00M | - |
| Capital expenditures | 0.00M | 0.00M |
| Change in working capital | -0.61M | -0.04M |
| Other non cash items | -4.60M | - |
| Free cash flow | -1.02M | -0.19M |
Sector: Financial Services Industry: Shell Companies
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
|---|---|---|---|---|---|---|
| DMII Drugs Made In America Acquisition II Corp. Ordinary Shares |
0.01 0.05% |
10.24 | 66.73 | - | - | 1.31 |
| CLUS CLUS |
- -% |
200.00 | - | - | 0.09 | 0.92 |
| SGDH Sgd Holdings Ltd |
- -% |
0.02 | - | - | 59741.55 | 0.56 |
| LION Lionsgate Studios Holding Corp. |
0.11 0.80% |
13.85 | - | 23.31 | 1.13 | 1.35 |
| QKIE QKIE |
- -% |
1.94 | - | - | 470.20 | - |
Drugs Made In America Acquisition II Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combination with one or more businesses. The company was incorporated in 2024 and is based in Fort Lauderdale, Florida.
1 East Broward Boulevard, Fort Lauderdale, FL, United States, 33301
954 870 3099
| Name | Title | Year Born |
|---|---|---|
| Mr. Roger Bendelac | Chief Executive Officer | 1957 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.